COMPOUND PROFILE / PEPTIDES & ANALOGUES
CT-388.
Research draftCT-388 is an experimental peptide dual GLP-1 and GIP receptor agonist.
Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.
Targeted source and identity review, not a systematic review or complete regulatory audit.
Overview
CT-388 is an experimental peptide dual GLP-1 and GIP receptor agonist.
Mechanism
It uses signalling-biased receptor activation intended to influence appetite and glucose control.
Human research
Published phase 1 research provides early weight and glycaemic findings; later readouts need separate review.
Preclinical & other research
Cell and animal models characterised receptor signalling and weight-related effects.
Safety & unknowns
Early trials cannot establish rare adverse effects or long-term outcomes.
Regulatory status
Investigational in reviewed sources; not interchangeable with tirzepatide.
Reported use & evidence
The supplied CT-388 profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.
Sources & references
Follow the cited records and registered research. Profiles remain research drafts.